Working… Menu

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03428802
Recruitment Status : Recruiting
First Posted : February 12, 2018
Last Update Posted : April 14, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eugenia Girda, MD, Rutgers Cancer Institute of New Jersey

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2, 2022
Estimated Study Completion Date : October 2, 2022